paxalisib Paxalisib is a KAZIA THERAPEUTICS LTD program in stage IV triple-negative breast cancer. Its next catalyst is a Readout in Q4 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Stage IV triple-negative breast cancer. Sponsor: KAZIA THERAPEUTICS LTD (KZIA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for paxalisib Paxalisib is a Readout in Q4 2027.
No FDA decision for paxalisib Paxalisib is in our archive yet.
In our records paxalisib Paxalisib is under review or in development for Stage IV triple-negative breast cancer.
KAZIA THERAPEUTICS LTD (KZIA).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.